Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.

Francesca GayAndreas GüntherMassimo OffidaniMonika EngelhardtMarco SalviniVittorio MontefuscoFrancesca PatriarcaSara AquinoWolfram PönischStefano SpadaNatalie SchubSilvia GentiliRalph WäschPaolo CorradiniChristian StrakaAntonio PalumboHermann EinseleMario BoccadoroPieter SonneveldMartin Gramatzki

Published in: Cancer (2021)

In heavily pretreated patients who have relapsed/refractory multiple myeloma, combined carfilzomib, bendamustine, and dexamethasone is an effective treatment option administered in the outpatient setting. Infection prophylaxis and attention to patients with cardiovascular predisposition are required.

Keyphrases

multiple myeloma
end stage renal disease
low dose
newly diagnosed
high dose
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
working memory
open label
randomized controlled trial
clinical trial
acute myeloid leukemia
chronic lymphocytic leukemia